A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 9/127 (2006.01) A61K 47/48 (2006.01)
Patent
CA 2362550
Nucleic acid-immunoliposome compositions useful as therapeutic agents are disclosed. These compositions preferably comprise (i) cationic liposomes, (ii) a single chain antibody fragment which binds to a transferrin receptor, and (iii) a nucleic acid encoding a wild type p53. These compositions target cells which express transferrin receptors, e.g., cancer cells. These compositions can be used therapeutically to treat persons or animals who have cancer, e.g., head and neck cancer, breast cancer or prostate cancer.
L'invention concerne des compositions d'immunoliposomes-acide nucléique utiles comme agents thérapeutiques. Ces compositions comportent de préférence: (1) des liposomes cationiques, (2) un fragment d'anticorps à chaîne unique qui se lie à un récepteur de transferrine, et (3) un acide nucléique codant pour un gène p53 de type sauvage. Ces compositions ciblent des cellules qui expriment des récepteurs de transferrine, p. ex. des cellules cancéreuses. Ces compositions peuvent être utilisées thérapeutiquement pour traiter des personnes ou des animaux atteints d'un cancer, p. ex. un cancer de la tête et du cou, un cancer du sein ou de la prostate.
Alexander William
Chang Esther H.
Huang Cheng-Cheng
Tang Wenhua
Xu Liang
Georgetown University
Osler Hoskin & Harcourt Llp
Synergene Therapeutics Inc.
LandOfFree
Antibody fragment-targeted immunoliposomes for systemic gene... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibody fragment-targeted immunoliposomes for systemic gene..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody fragment-targeted immunoliposomes for systemic gene... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1483799